Publications
Detailed Information
Clinical adoption patterns of 0.35 Tesla MR-guided radiation therapy in Europe and Asia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Slotman, Berend J. | - |
dc.contributor.author | Clark, Mary A. | - |
dc.contributor.author | Özyar, Enis | - |
dc.contributor.author | Kim, Myungsoo | - |
dc.contributor.author | Itami, Jun | - |
dc.contributor.author | Tallet, Agnès | - |
dc.contributor.author | Debus, Jürgen | - |
dc.contributor.author | Pfeffer, Raphael | - |
dc.contributor.author | Gentile, PierCarlo | - |
dc.contributor.author | Hama, Yukihiro | - |
dc.contributor.author | Andratschke, Nicolaus | - |
dc.contributor.author | Riou, Olivier | - |
dc.contributor.author | Camilleri, Philip | - |
dc.contributor.author | Belka, Claus | - |
dc.contributor.author | Quivrin, Magali | - |
dc.contributor.author | Kim, BoKyong | - |
dc.contributor.author | Pedersen, Anders | - |
dc.contributor.author | van Overeem Felter, Mette | - |
dc.contributor.author | Kim, Young I. | - |
dc.contributor.author | Kim, Jin H. | - |
dc.contributor.author | Fuss, Martin | - |
dc.contributor.author | Valentini, Vincenzo | - |
dc.date.accessioned | 2022-09-30T05:59:45Z | - |
dc.date.available | 2022-09-30T05:59:45Z | - |
dc.date.issued | 2022-08-22 | - |
dc.identifier.citation | Radiation Oncology. 2022 Aug 22;17(1):146 | - |
dc.identifier.uri | https://doi.org/10.1186/s13014-022-02114-2 | - |
dc.identifier.uri | https://hdl.handle.net/10371/185094 | - |
dc.description.abstract | Abstract
Background Magnetic resonance-guided radiotherapy (MRgRT) utilization is rapidly expanding, driven by advanced capabilities including better soft tissue imaging, continuous intrafraction target visualization, automatic triggered beam delivery, and the availability of on-table adaptive replanning. Our objective was to describe patterns of 0.35 Tesla (T)-MRgRT utilization in Europe and Asia among early adopters of this novel technology. Methods Anonymized administrative data from all 0.35T-MRgRT treatment systems in Europe and Asia were extracted for patients who completed treatment from 2015 to 2020. Detailed treatment information was analyzed for all MR-linear accelerators (linac) and -cobalt systems. Results From 2015 through the end of 2020, there were 5796 completed treatment courses delivered in 46,389 individual fractions. 23.5% of fractions were adapted. Ultra-hypofractionated (UHfx) dose schedules (1–5 fractions) were delivered for 63.5% of courses, with 57.8% of UHfx fractions adapted on-table. The most commonly treated tumor types were prostate (23.5%), liver (14.5%), lung (12.3%), pancreas (11.2%), and breast (8.0%), with increasing compound annual growth rates (CAGRs) in numbers of courses from 2015 through 2020 (pancreas: 157.1%; prostate: 120.9%; lung: 136.0%; liver: 134.2%). Conclusions This is the first comprehensive study reporting patterns of utilization among early adopters of a 0.35T-MRgRT system in Europe and Asia. Intrafraction MR image-guidance, advanced motion management, and increasing adoption of on-table adaptive RT have accelerated a transition to UHfx regimens. MRgRT has been predominantly used to treat tumors in the upper abdomen, pelvis and lungs, and increasingly with adaptive replanning, which is a radical departure from legacy radiotherapy practices. | - |
dc.title | Clinical adoption patterns of 0.35 Tesla MR-guided radiation therapy in Europe and Asia | - |
dc.type | Journal Article | - |
dc.language.rfc3066 | en | - |
dc.rights.holder | The Author(s) | - |
dc.date.updated | 2022-08-28T03:12:46Z | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.